Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami

HIV Medicine

Volumn 12, Issue 2, 2011, Pages 78-86

  Baum, M K ^a   Sales, S ^a   Jayaweera, D T ^b   Lai, S ^c   Bradwin, G ^d   Rafie, C ^a   Page, J B ^b   Campa, A ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Antioxidants; HCV; HIV; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIRETROVIRUS AGENT; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; RETINOL; SELENIUM;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE TO PLATELET RATIO INDEX; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; BODY MASS; CD4 LYMPHOCYTE COUNT; CORRELATION ANALYSIS; DRUG ABUSE; FEMALE; FIBROSIS INDEX; HEMATOLOGICAL PARAMETERS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; UNITED STATES; VIRUS LOAD; VITAMIN BLOOD LEVEL; ZINC BLOOD LEVEL;

ADULT; ANTIOXIDANTS; CD4 LYMPHOCYTE COUNT; FEMALE; FLORIDA; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; OXIDATIVE STRESS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 79954587396     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00849.x     Document Type: Article

References (57)

1. Mayor AM, Gomez MA, Fernandez DM, Rios-Olivares E, Thomas JC, Hunter RF. Morbidity and mortality profile of human immunodeficiency virus-infected patients with and without hepatitis C co-infection. Am J Trop Med Hyg 2006; 74: 239-245.
2. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-247.
3. Management of Chronic Hepatitis C. Agency for Healthcare Research and Quality, NIH Consensus Report, Evidence Report 60, issued 8/27/02. Available at (accessed 10 February 2010).
4. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36 (Suppl 5): 47-56.
5. Cornianu M, Dema A, Taban S, Lazar D, Lazar E, Costi S. Hepatic steatosis associated with hepatitis C virus infection. Rom J Morphol Embryol 2005; 46: 283-289.
6. Garcia-Mediavilla MV, Sanchez-Campos S, Gonzalez-Perez P et al. Differential contribution of hepatitis C virus NS5A and core proteins to the induction of oxidative and nitrosative stress in human hepatocyte-derived cells. J Hepatol 2005; 43: 606-613.
7. Korenaga M, Okuda M, Otani K, Wang T, Li Y, Weinman SA. Mitochondrial dysfunction in hepatitis C. J Clin Gastroenterol 2005; 39: S162-S166.
8. Parola M, Robino G. Oxidative stress related molecules and liver fibrosis. J Hepatol 2001; 35: 297-306.
9. De Maria N, Colantoni A, Fagiuoli S et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996; 21: 291-295.
10. Paradis V, Kollinger M, Fabre M et al. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997; 26: 135-142.
11. Gil L, Martinez G, Gonzalez I et al. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacol Res 2003; 47: 217-224.
12. Serejo F, Emerit I, Filipe PM et al. Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features. Can J Gastroenterol 2003; 17: 644-650.
13. Romero MJ, Bosche-Morell F, Romero B, Todrigo JM, Serra MA, Romero FJ. Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Free Radic Biol Med 1998; 25: 993-997.
14. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2634-2639.
15. Price TO, Uras F, Banks WA, Ercal N. A novel antioxidant N-acetylcysteine amide prevents gp120- and Tat-induced oxidative stress in brain endothelial cells. Exp Neurol 2006; 201: 193-202.
16. de Mendoza C, Sánchez-Conde M, Timmermans E et al. Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin. Antivir Ther 2005; 10: 557-561.
17. Stehbens WE. Oxidative stress in viral hepatitis and AIDS. Exp Mol Path 2004; 77: 121-132.
18. Repetto M, Reides C, Gomez Carretero ML, Costa M, Griemberg G, Llesuy S. Oxidative stress in blood of HIV infected patients. Clin Chim Acta 1996; 255: 107-117.
19. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radic Biol Med 1995; 19: 523-528.
20. Yano S, Colon M, Yano N. An increase of acidic isoform of catalase in red blood cells from HIV(+) population. Mol Cell Biochem 1996; 165: 77-81.
21. Gronbaek K, Sonne J, Ring-Larsen H, Poulsen HE, Friis H, Bygum Krarup H. Viral load is a negative predictor of antioxidant levels in hepatitis C patients. Scand J Infect Dis 2005; 37: 686-689.
22. Baum K. Role of micronutrients in HIV-infected intravenous drug users. J Acquir Immune Defic Syndr Hum Retrovirol 2000; 25: S49-S52.
23. Jackson JB, Smith K, Knott C et al. Sensitivity of the Procleix HIV-1/HCV assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA in a high-risk population. J Clin Microbiol 2002; 40: 2387-2391.
24. Sterling RK, Lissen E, Clumeck N et al. for the APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
25. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002; 60: 289-293.
26. Bujanda L, Hijona E, Larzabal M et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008; 8: 40.
27. Stephensen CB, Marquis GS, Douglas SD, Wilson CM. Immune activation and oxidative damage in HIV-positive and HIV-negative adolescents. J Acquir Immune Defic Syndr 2005; 38: 180-190.
28. Ngondi JL, Oben J, Musoro FD, Etame SLH, Mbanya D. The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. AIDS Res Ther 2006; 3: 19.
29. Baum MK, Shor-Posner G, Lu Y et al. Micronutrients and HIV-1 disease progression. AIDS 1995; 9: 1051-1056.
30. Tang AM, Graham NM, Kirby AJ, McCall LD, Willett WC, Saah AJ. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men. Am J Epidemiol 1993; 138: 937-951.
31. Cardin R, Saccoccio G, Masutti F et al. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. J Hepatol 2001; 34: 587-592.
32. Valgimigli M, Valgimigli L, Trere D et al. Oxidative stress EPR measurement in human liver by radical-probe technique: correlation with etiology, histology and cell proliferation. Free Radic Res 2002; 36: 939-948.
33. Barbaro G, Di Lorenzo G, Asti A et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol 1999; 94: 2198-2205.
34. Barbaro G, Di Lorenzo G, Ribersani M et al. Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 1999; 30: 774-782.
35. Sumida Y, Nakashima T, Yoh T et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000; 33: 616-622.
36. Farinati F, Cardin R, D'Errico et al. Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIBI Ki67 in archival material: the role of etiology, disease activity, iron and lipid peroxidation. Hepatology 1996; 23: 1468-1475.
37. Farinati F, Cardin R, DeMarie N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-456.
38. Lim HL, Myers BM, Hamilton BA, Davis GL, Lau JY. Plasma glutathione concentration in patients with chronic hepatitis C virus infection. J Viral Hepat 1995; 2: 211-214.
39. Svegliati Baroni G, D'Ambrosio L, Ferretti G et al. Fibrogenetic effect of oxidative stress on rat hepatic stellate cells. Hepatology 1998; 27: 720-726.
40. Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375.
41. Jain SK, Pemberton PW, Smith A et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatology 2002; 36: 805-811.
42. Takagi H, Nagamine T, Abe T et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat 2001; 8: 367-371.
43. Galai N, Vlahov D, Margolick JB, Chen K, Graham NMH, Munoz A. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immun Defic Syndr 1995; 8: 66-74.
44. Watson RR, Mohs ME. Effects of morphine, cocaine, and heroin on nutrition, In: Pawlowski P. ed. Alcohol Immunomodulation, and AIDS. New York: Alan R Wiley-Liss, 1990: 413-418.
45. Shor-Posner G, Baum MK. Nutritional Alterations in HIV-1 seropositive and seronegative drug users. Nutrition 1996; 12: 555-556.
46. von Herbay A, Stahl W, Niederau C, von Laar J, Strohmeyer G, Sies H. Diminished plasma levels of vitamin E in patients with severe viral hepatitis. Free Radic Res 1996; 25: 461-466.
47. Newsome PN, Beldon I, Moussa Y et al. Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. Aliment Pharmacol Ther 2000; 14: 1295-1301.
48. Tapell AL. Lipid peroxidation damage to cell components. Fed Proc 1973; 32: 1870-1874.
49. Murakami Y, Koyabu T, Kawashima A et al. Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin. J Nutr Sci Vitaminol 2007; 53: 213-218.
50. Moustafa AH, Ali EM, Mohamed TM, Abdou HI. Oxidative stress and thyroid hormones in patients with liver diseases. Eur J Intern Med 2009; 20: 703-708.
51. Look MP, Gerard A, Rao GS et al. Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial. Antiviral Res 1999; 43: 113-122.
52. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069-1073.
53. Ljubuncic P, Konikoff FM, Blendis LM, Bomzon A. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection. Hepatogastroenterology 2005; 52: 1191-1196.
54. Beloqui O, Prieto J, Suarez M et al. N-acetylcysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13: 279-282.
55. Mahmood S, Yamada G, Niiyama G et al. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic Res 2003; 37: 781-785.
56. Dahari H, Layden-Almer JE, Perelson AS, Layden TJ. Hepatitis C viral kinetics in special populations. Curr Hepat Rep 2008; 7: 97-105.
57. Beisel WR. AIDS. Chapter 32, In: Gershwin ME, German JB, Keen CL. eds. Nutrition and Immunology: Principles and Practices. Totowa, NJ: Humana Press, 2000: 389-403.